September 26, 2015Seminars in Thrombosis and Hemostasis
Management of Bleeding Associated with New Oral Anticoagulants
Population
Patients receiving non-VKA oral anticoagulants for prevention and treatment of thromboembolism
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
NOACs offer practical advantages for thromboembolism management; leaves open need for targeted trials in underrepresented subgroups.
Structured PICO
P
Population
Patients receiving non-VKA oral anticoagulants (NOACs: dabigatran, apixaban, rivaroxaban, edoxaban) for prevention and treatment of thromboembolism
I
Intervention
Management strategies and treatment algorithm for NOAC-associated bleeding
This review provides a practical treatment algorithm to help physicians manage bleeding complications in patients taking novel oral anticoagulants.
Cite This Study
Bonfanti et al. (2015) studied this question.